• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Trokendi XR (topiramate)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Trokendi XR (topiramate)

  • Profile

Profile

Contact Information

Contact: Supernus Pharmaceuticals
Website: http://www.trokendixr.com/

Currently Enrolling Trials

    Show More

    General Information

    Trokendi XR is an extended-release formulation of topiramate, an anticonvulsant.

    Trokendi XR is specifically indicated as initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures and adjunctive therapy in patients 6 years of age and older with partial onset or primary generalized tonic-clonic seizures. Trokendi XR is also indicated as adjunctive therapy in patients 6 years of age and older with seizures associated with Lennox-Gastaut syndrome.

    Mechanism of Action

    Trokendi XR is an extended-release formulation of topiramate, an anticonvulsant. The precise mechanisms by which topiramate exerts its anticonvulsant effects are unknown; however, preclinical studies have revealed four properties that may contribute to topiramate's efficacy for epilepsy. Electrophysiological and biochemical evidence suggests that topiramate, at pharmacologically relevant concentrations, blocks voltage-dependent sodium channels, augments the activity of the neurotransmitter gamma-aminobutyrate at some subtypes of the GABA-A receptor, antagonizes the AMPA/kainate subtype of the glutamate receptor and inhibits the carbonic anhydrase enzyme.

    Side Effects

    Adverse events associated with the use of Topamax XR may include, but are not limited to, the following:

    • paresthesia
    • anorexia
    • weight decrease
    • fatigue
    • dizziness
    • somnolence
    • nervousness
    • psychomotor slowing
    • difficulty with memory
    • difficulty with concentration/attention
    • cognitive problems
    • confusion
    • mood problems
    • fever
    • infection
    • flushing

    Dosing/Administration

    Trokendi XR is supplied as a capsule for oral administration. The recommended dose regimen is as follows:
    Monotherapy use
    Adults and pediatrics 10 years and older with partial onset or primary generalized tonic-clonic seizures: 400 mg orally once daily. Titrate Trokendi XR according to the following schedule:
    Week 1 50 mg once daily
    Week 2 100 mg once daily
    Week 3 150 mg once daily
    Week 4 200 mg once daily
    Week 5 300 mg once daily
    Week 6 400 mg once daily

    Adjunctive therapy use
    Adults (17 years of age and older) - partial onset seizures, primary generalized tonic-clonic seizures or Lennox-Gastaut syndrome: partial onset seizures or Lennox-Gastaut syndrome - 200 mg to 400 mg orally once daily; primary generalized tonic-clonic seizures - 400 mg orally once daily. Initiate therapy at 25 mg to 50 mg once daily followed by titration to an effective dose in increments of 25 mg to 50mg every week.

    Pediatrics (ages 6 years to 16 years) - partial onset seizures, primary generalized tonic-clonic seizures or Lennox-Gastaut syndrome: approximately 5 mg/kg to 9 mg/kg orally once daily. Begin titration at 25 mg once daily (based on a range of 1 mg/kg/day to 3 mg/kg/day) given nightly for the first week. Subsequently, increase the dosage at one- or two­-week intervals by increments of 1 mg/kg to 3 mg/kg to achieve optimal clinical response.

    Clinical Trial Results

    The FDA approval of Trokendi XR was based on studies using an immediate-release formulation of topiramate and the demonstration of the pharmacokinetic equivalence of Trokendi XR to immediate-release topiramate through the analysis of concentrations and cumulative AUCs at multiple time points.

     

    Approval Date: 2013-08-01
    Company Name: Supernus Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing